PE20081545A1 - Derivados de sulfonamida como inhibidores de acido graso sintasas - Google Patents
Derivados de sulfonamida como inhibidores de acido graso sintasasInfo
- Publication number
- PE20081545A1 PE20081545A1 PE2008000005A PE2008000005A PE20081545A1 PE 20081545 A1 PE20081545 A1 PE 20081545A1 PE 2008000005 A PE2008000005 A PE 2008000005A PE 2008000005 A PE2008000005 A PE 2008000005A PE 20081545 A1 PE20081545 A1 PE 20081545A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- alkyl
- fatty acid
- cyane
- alcoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
REFERIDA A UN DERIVADO DE SULFONAMIDA DE FORMULA (I), DONDE R1 ES ALQUILO C1-C6, CICLOALQUILO C3-C10, ALQUINILO C2-C6, ENTRE OTROS; R2 ES H, CIANO, HALO,ALCOXI C1-C3, ENTRE OTROS; R3 ES H, CIANO, HALO, ALCOXI C1-C3, ENTRE OTROS; R4 ES ALQUILO C1-C3, ALCOXI C1-C3, HALO, ENTRE OTROS; R5 Y R5' SON H, HALO, CIANO, ALQUILO C1-C3, ENTRE OTROS; R6 Y R6' SON H, HALO, CIANO, ALQUILO C1-C3, ENTRE OTROS; R7 ES H U OH. SON COMPUESTOS PREFERIDOS: N-[5-[4-(4-CIANOFENIL)PIPERIDIN-1-CARBONIL]-2-METIL-FENIL]METANSULFONAMIDA, N-[5-[4-(4-CIANOFENIL)PIPERIDIN-1-CARBONIL]-2-METIL-FENIL]-2-FLUORO-BENCENSULFONAMIDA, 4-CLORO-N-[5-[4-(4-CIANOFENIL)PIPERIDIN-1-CARBONIL-2-METIL-FENIL]BENCENSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACIDO GRASO SINTASA (FAS) Y SON UTILES EN EL TRATAMIENTO DE LA OBESIDAD Y DIABETES MELLITUS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87119206P | 2006-12-21 | 2006-12-21 | |
US91023207P | 2007-04-05 | 2007-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081545A1 true PE20081545A1 (es) | 2009-01-11 |
Family
ID=39166817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000005A PE20081545A1 (es) | 2006-12-21 | 2008-01-02 | Derivados de sulfonamida como inhibidores de acido graso sintasas |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090105305A1 (es) |
AR (1) | AR064495A1 (es) |
CL (1) | CL2007003803A1 (es) |
PE (1) | PE20081545A1 (es) |
TW (1) | TW200831092A (es) |
UY (1) | UY30809A1 (es) |
WO (1) | WO2008075070A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
WO2007140439A2 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2008121558A1 (en) | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7872033B2 (en) * | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) * | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
CA2716857A1 (en) | 2008-03-11 | 2009-09-17 | Teodozyi Kolasa | Novel compounds as cannabinoid receptor ligands |
US8404866B2 (en) | 2008-09-03 | 2013-03-26 | Florida State University Research Foundation | Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors |
US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8859596B2 (en) * | 2008-09-16 | 2014-10-14 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
PA8854001A1 (es) * | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
AR075442A1 (es) * | 2009-02-16 | 2011-03-30 | Abbott Gmbh & Co Kg | Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia |
US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
WO2012064642A1 (en) * | 2010-11-08 | 2012-05-18 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
KR101930106B1 (ko) * | 2011-03-08 | 2018-12-17 | 3-브이 바이오사이언시스, 인코포레이티드 | 지질 합성의 헤테로사이클릭 조절자 |
US8871790B2 (en) | 2011-03-08 | 2014-10-28 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
US9624173B2 (en) | 2011-03-08 | 2017-04-18 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
WO2013028447A1 (en) | 2011-08-19 | 2013-02-28 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
CN104080777B (zh) * | 2012-01-31 | 2015-12-09 | 伊莱利利公司 | 用作mogat-2抑制剂的吗啉基衍生物 |
SG11201500024YA (en) | 2012-07-03 | 2015-03-30 | 3 V Biosciences Inc | Heterocyclic modulators of lipid synthesis |
EA201590696A1 (ru) * | 2012-11-06 | 2015-08-31 | Эли Лилли Энд Компани | Новые бензилсульфонамидные соединения, подходящие в качестве ингибиторов mogat-2 |
CN103420824B (zh) * | 2012-11-19 | 2015-06-17 | 烟台万润精细化工股份有限公司 | 烷氧基甲基苯甲酸的制备方法 |
MY191366A (en) | 2013-03-13 | 2022-06-20 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
WO2015084606A1 (en) * | 2013-12-03 | 2015-06-11 | Janssen Pharmaceutica Nv | Benzamide derivative useful as fasn inhibitors for the treatment of cancer |
ES2841137T3 (es) * | 2013-12-20 | 2021-07-07 | Sagimet Biosciences Inc | Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos |
AU2015204907B2 (en) | 2014-01-07 | 2018-08-02 | Sagimet Biosciences Inc. | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections |
WO2016025816A1 (en) | 2014-08-15 | 2016-02-18 | 3-V Biosciences, Inc. | Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer |
JP6758314B2 (ja) | 2015-03-19 | 2020-09-23 | サギメット バイオサイエンシーズ インコーポレイテッド | 脂質合成の複素環式調節因子 |
ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
PE20180572A1 (es) | 2015-06-18 | 2018-04-04 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos |
CN105153145B (zh) * | 2015-07-29 | 2018-10-30 | 广州市广金投资管理有限公司 | 芳基哌嗪衍生物ⅱ及其盐、制备方法和用途 |
CN105130921B (zh) * | 2015-07-29 | 2018-04-06 | 广州市广金投资管理有限公司 | 芳基哌嗪衍生物ⅰ及其盐、制备方法和用途 |
EP3538088A1 (en) * | 2016-11-11 | 2019-09-18 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
WO2019204505A2 (en) * | 2018-04-18 | 2019-10-24 | Theras, Inc. | K-ras modulators with a vinyl sulfonamide moiety |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
EP4319734A2 (en) | 2021-04-07 | 2024-02-14 | Hadasit Medical Research Services&Development Ltd. | Prostaglandin receptor 3 (ep3) antagonists for use in the treatment of diabetes |
WO2022217239A1 (en) * | 2021-04-09 | 2022-10-13 | Board Of Regents, The University Of Texas System | Inhibitors of pu.1 for the treatment of disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6423704B2 (en) * | 1995-12-20 | 2002-07-23 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
CA2509711A1 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
-
2007
- 2007-12-18 TW TW096148503A patent/TW200831092A/zh unknown
- 2007-12-19 UY UY30809A patent/UY30809A1/es unknown
- 2007-12-20 US US11/961,850 patent/US20090105305A1/en not_active Abandoned
- 2007-12-20 WO PCT/GB2007/004920 patent/WO2008075070A1/en active Application Filing
- 2007-12-21 AR ARP070105860A patent/AR064495A1/es unknown
- 2007-12-21 CL CL200703803A patent/CL2007003803A1/es unknown
-
2008
- 2008-01-02 PE PE2008000005A patent/PE20081545A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2008075070A1 (en) | 2008-06-26 |
US20090105305A1 (en) | 2009-04-23 |
CL2007003803A1 (es) | 2008-08-01 |
UY30809A1 (es) | 2008-07-31 |
AR064495A1 (es) | 2009-04-08 |
TW200831092A (en) | 2008-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
PE20090813A1 (es) | Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa | |
PE20080843A1 (es) | Inhibidores de renina y metodo para su utilizacion | |
PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
PE20021014A1 (es) | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad | |
PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
PE20110136A1 (es) | Compuestos organicos | |
PE20061357A1 (es) | COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1 | |
PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
PE20130384A1 (es) | Derivados de benzotiazepina | |
PE20081487A1 (es) | DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1 | |
PE20061099A1 (es) | Compuestos de piridil acido acetico como inhibidores de peptidasa | |
PE20081532A1 (es) | Compuestos novedosos | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
UY31986A (es) | Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
PE20071223A1 (es) | Procedimiento de preparacion de derivados de acil-amino-alquilen-amida | |
PE20070503A1 (es) | Compuestos derivados de pirazol como inhibidores del glucagon | |
MY148566A (en) | Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes | |
PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
PE20090903A1 (es) | Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa | |
PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
PE20080768A1 (es) | Compuestos de isoindolina 5-sustituidos | |
PE20081704A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |